Trials / Completed
CompletedNCT05132101
Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea
Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a 1st Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,758 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the real-world prescription patterns of Palbociclib in breast cancer (BC) patients who were treated with Palbociclib in combination with AI as a 1st line of therapy using the national health insurance claims data in South Korea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Patients who received Palbociclib as first line therapy in MBC setting | Patients who received Palbociclib as first line therapy in MBC setting |
Timeline
- Start date
- 2021-12-20
- Primary completion
- 2022-03-14
- Completion
- 2022-03-14
- First posted
- 2021-11-24
- Last updated
- 2025-06-19
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05132101. Inclusion in this directory is not an endorsement.